Bristol Myers Squibb bolsters cancer presence with $4.8B Mirati acquisition

The latest stories trending on MedCity News.

Editor's Pick

Top Story Bristol Myers Squibb Bolsters Its Cancer Presence With $4.8B Mirati Acquisition Acquiring Mirati Therapeutics brings Bristol Myers Squibb Krazati, one of two FDA-approved therapies addressing a KRAS cancer mutation. The deal comes as BMS looks to add revenue-generating products as patent expirations loom for several of its cancer products. Sponsored Content Payer's Place: Dawn Maroney, Alignment Health Presented by HLTH and MedCity News Dawn Maroney of Alignment Health highlights how they provide healthcare that helps patients be financially responsible and receive the care needed.  How the company utilizes course data and technology to help advance those needs and connect the patients with better practices and outcomes. Click here to watch the full interview!

Featured News

Bessemer Venture Partners Unveils State of Health Tech Report at HLTH 2023 The report maps out the health tech sector's current position in the innovation hype cycle, which business models are most resilient, and how the industry can move out of the trough of disillusionment. It also offered predictions for health tech trends in 2024. Why One Expert Thinks the Medicare Drug Price Negotiation Program Is Here to Stay Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. Her reasoning? Every other high income nation has been negotiating prices with drugmakers for years, and the program is widely popular in the U.S. among pretty much everyone who isn't a pharma company, she said during a session at Engage at HLTH. How AI Can Fix the Broken Clinical Trial Process By combining AI with human expertise and oversight, we have the potential to revolutionize the clinical trial process—and most importantly, extend and save lives. From Promise to Impact: The Evolution of AI in Medical Imaging for Population Health and ROI The ultimate challenge for the broader adoption of AI in medical imaging remains the same: demonstrating to healthcare institutions that it provides a clear ROI. FDA Rejection Is a Delay, Not a Detour for Alnylam's Aim to Treat Heart Disorder Despite an affirmative FDA advisory committee vote, the agency declined to approve Alnylam Pharmaceuticals' Onpattro for treating the heart complications caused by a rare, inherited protein disorder. But Alnylam has other drugs candidates for the disease, including one expected to post Phase 3 data in the first half of 2024. Digital Health Consolidation Is Meant To Happen, VCs say Endless digital health solutions have emerged over the last few years. But eventually, they'll have to consolidate — and that's part of the cycle, investors said during a panel discussion on Sunday. Venture Capital Firm Shares Ambitious Value-Based Care Strategy: Buy a Health System The opening day of the HLTH 2023 event offered a surprising announcement from venture capital firm General Catalyst. Weight Watchers CEO called for a change in how we talk about obesity. ENGAGE at HLTH offered compelling discussions around retail health, prescription drug prices and investment trends.

Resources

MedCity Pivot Podcast: Tackling Rare Disease With Someone Who Was Touched By It Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe